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Abstract 
Activation of the ATR kinase following perturbations to DNA replication relies 
on a complex mechanism involving ATR recruitment to RPA-coated single-
stranded DNA via its binding partner ATRIP and stimulation of ATR kinase 
activity by TopBP1. Here, we discovered an independent ATR activation 
pathway in vertebrates, mediated by the uncharacterized protein ETAA1 
(Ewing’s tumor-associated antigen 1). Human ETAA1 accumulates at DNA 
damage sites via dual RPA-binding motifs and promotes replication fork 
progression and integrity, ATR signaling and cell survival after genotoxic 
insults. Mechanistically, this requires a conserved domain in ETAA1 that 
potently and directly stimulates ATR kinase activity independently of TopBP1. 
Simultaneous loss of ETAA1 and TopBP1 gives rise to synthetic lethality 
characterized by massive genome instability and abrogation of ATR-dependent 
signaling. Our findings demonstrate that parallel TopBP1- and ETAA1-
mediated pathways underlie ATR activation and that their combined action is 
essential for coping with replication stress. 
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Introduction 
Alterations to the content and organization of cellular genomes, inflicted by numerous 
genotoxic insults, may lead to pathological conditions such as cancer, premature 
aging and neurodegeneration1,2. To mitigate this threat, cells mount a coordinated 
DNA damage response (DDR) that promotes repair of DNA lesions and delays cell 
cycle progression until genome integrity has been restored3,4. The phosphatidyl 
inositol 3’ kinase-related kinases ATM and ATR are master organizers of the DDR 
that trigger damage-specific signaling cascades through direct phosphorylation of 
large numbers of effector proteins, including the downstream checkpoint kinases 
Chk1 and Chk24-10. The critical physiological importance of these kinases in 
protecting genome stability is illustrated by patients with Ataxia telangiectasia and 
Seckel syndromes, caused by mutations in ATM and ATR, respectively, which 
manifest with a range of severe disabilities11, 12. Whereas ATM is mainly activated by 
DNA double-strand breaks (DSBs), ATR is the major kinase responding to replication 
stress, a potentially deleterious condition defined by a slowdown or block to 
replication fork progression, which arises frequently from a broad range of 
perturbations including DNA damage, nucleotide shortage, and replication-
transcription collisions13, 14. ATR is essential for ensuring the fidelity of DNA 
replication after such insults, suppressing new origin firing, preventing fork collapse 
and promoting the restart of stalled forks. Consequently, disruption of the ATR gene 
causes early embryonic lethality in mice15, 16.  
 
Replication Protein A (RPA)-coated single-stranded DNA (ssDNA) regions generated 
by uncoupling of replicative helicase and polymerase movements upon fork stalling 
or by DSB end resection provide a main stimulus for activation of ATR, which is 
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recruited to these structures via its obligate binding partner ATRIP17-19. In parallel, the 
PCNA-like Rad9-Rad1-Hus1 (9-1-1) complex is loaded onto junctions of ssDNA and 
double-stranded DNA (dsDNA), leading to recruitment of the multi-BRCT domain-
containing protein TopBP1 via Rad9 phosphorylation, the Mre11-Rad50-Nbs1 
(MRN) complex, and the RHINO protein20-25.	TopBP1 directly stimulates ATR kinase 
activity by means of an ATR-activating domain (AAD) that may promote 
conformational changes of the ATR kinase domain26, 27, and whose integrity is 
essential for viability in mice28. 	
 
While TopBP1 is the only protein known to harbor an AAD in higher eukaryotes, two 
additional proteins, the Rad9 orthologue Ddc1 and the exonuclease Dna2, also contain 
AADs in the yeast S. cerevisiae29, 30. These factors play partially redundant roles in 
promoting activation of Mec1, the ATR orthologue in budding yeast, and 
simultaneous knockout of all three AAD-containing proteins is required to abrogate 
Mec1-dependent checkpoint signaling in S phase30. Whether ATR activation in higher 
eukaryotes involves AAD-containing proteins other than TopBP1 is therefore an 
important outstanding question. In this study, we demonstrate that the uncharacterized 
protein ETAA1 (Ewing’s tumor-associated antigen 1) is an RPA-binding protein that 
harbors a potent AAD and operates in parallel with, but independent of, the canonical 
9-1-1/TopBP1 axis to promote ATR signaling upon replication stress. Loss of ETAA1 
disrupts the integrity of the DNA replication programme, sensitizes cells to 
replication stress and displays synthetic lethality with TopBP1 depletion, 
characterized by abrogation of ATR-dependent checkpoint signaling and massive 
genomic instability. Thus, ATR activation in human cells relies on dual TopBP1- and 
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ETAA1-mediated pathways whose combined action is essential for coping with 
replication stress. 
 
 
Results  
Systematic profiling of DNA double-strand break (DSB)-containing chromatin  
We recently developed a mass spectrometry-based approach (CHROMASS) to 
systematically profile protein recruitment to chromatin containing DNA interstrand 
crosslinks in Xenopus egg extracts31. To extend these surveys, we applied 
CHROMASS and label-free mass spectrometry to study protein enrichment dynamics 
at chromatin modified with nuclease-generated DNA double-strand breaks (DSBs) 
(Figure 1a). At early time points, we observed strong and near-exclusive enrichment 
of virtually all known core factors in classical non-homologous end-joining (c-NHEJ), 
a major DSB repair pathway (Figure 1b,c;Table S1,S2). At later time points, the 
ssDNA-binding RPA complex (rfa1-3) and known RPA interactors (including ATR-
ATRIP, SMARCAL1 (smal1), rfwd3 and helb) also became enriched on the damaged 
chromatin (Figure 1b,d;Table S1,S2), indicative of progressive DSB end resection. In 
addition to many established DSB repair factors, these screens revealed potential new 
components of DNA damage signaling and repair pathways, one of which we 
characterize below. These data demonstrate that CHROMASS is a powerful method 
for comprehensive profiling of the dynamic protein landscape at DSB-modified 
chromatin. 
 
ETAA1 is a potential DDR factor linked to RPA 
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Among factors showing recruitment to DSB-containing chromatin in the Xenopus 
system, we identified an uncharacterized protein, etaa1, which became markedly 
enriched on damaged chromatin together with RPA and RPA-binding factors (Figure 
1b-d). High sequence coverage allowed robust quantification of etaa1 across the 
dataset, revealing strikingly similar intensity profiles of etaa1, RPA subunits and 
known RPA interactors (Figure S1a-c). Moreover, etaa1 showed strong enrichment on 
undamaged chromatin upon inhibition of DNA polymerases by Aphidicolin (Figure 
S1d;Table S3), which causes extensive RPA-ssDNA generation through uncoupling 
of replicative polymerases and helicases17. This suggests that the function of etaa1 is 
tightly linked to RPA.  
 
To characterize the cellular function of etaa1, we focused on the human orthologue, 
ETAA1 (Ewing’s tumor-associated antigen 1), an uncharacterized 926-amino acid 
protein32. When expressed stably in human cells, GFP-tagged ETAA1 underwent 
prominent redistribution to laser-induced DSBs demarcated by γH2AX positivity 
(Figure 1e,f). Consistent with the strong clustering of etaa1 with RPA and RPA-
interactors in CHROMASS experiments (Figure S1b), ETAA1 was only recruited to 
DNA damage sites in cells displaying RPA1 accumulation, and the ETAA1 and 
RPA1 signals perfectly co-localized in a microfoci-like pattern contained within the 
more expanded γH2AX regions at laser stripes (Figure 1e,f)33. ETAA1 also formed 
nuclear foci colocalizing with RPA after short-term exposure to Camptothecin (CPT), 
which induces replication-dependent DSBs, and Hydroxyurea (HU), which causes 
helicase-polymerase uncoupling but little DSB formation (Figure 1g). We conclude 
that ETAA1 is recruited to RPA-coated ssDNA regions generated upon genotoxic 
insults in vertebrate cells. 
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ETAA1 accumulates at DNA damage sites through direct binding to RPA  
The observations above suggested that ETAA1 might be recruited to DNA damage 
sites through direct binding to RPA. Consistently, inhibition of RPA accumulation at 
DSB sites by knockdown of CtIP, a key factor in DSB end resection34, or RPA1, 
suppressed ETAA1 recruitment to damaged DNA, while depletion of core 
homologous recombination (HR) factors such as BRCA2 or RAD51 had no effect 
(Figure 2a;S2a). Moreover, ETAA1 and RPA subunits interacted firmly in reciprocal 
co-immunoprecipitation assays (Figure 2b,c). Expression of a series of ETAA1 
fragments showed that its C-terminal portion contained the RPA-binding determinant 
(Figure S2b). Inspection of the primary sequence of this region revealed an 
evolutionarily conserved motif in the extreme C-terminus of ETAA1 showing striking 
homology with the RPA2-binding motifs in SMARCAL1, XPA and TIPIN (Figure 
2d)35-37. Indeed, removal of the C-terminal region in RPA2 recognized by these motifs 
impaired its interaction with ETAA1 (Figure 2c). Deletion of the ETAA1 C-terminus 
containing the putative RPA2-binding motif (ΔRBM2) or point mutations of key 
conserved residues predicted to impair its functional integrity35, 36 suppressed the 
RPA-binding ability of ETAA1 and its recruitment to DSBs (Figure 2b,e,f;S2c-f). 
However, the ETAA1 ΔRBM2 mutant displayed weak accumulation at DNA damage 
sites in a small proportion of cells (Figure 2e,f), suggesting that additional sequence 
determinants in ETAA1 also contribute to its DNA damage recruitment. To this end, 
we noticed a sequence in the central portion of ETAA1 with similarity to known 
RPA1-binding motifs in ATRIP, NBS1 and RAD9 (Figure 2d)38. While deletion of 
this sequence alone (ΔRBM1) had no impact on the ability of ETAA1 to interact with 
RPA and DNA damage sites, simultaneous ablation of both RPA-binding motifs 
(ΔRBM1+2) fully suppressed ETAA1 recruitment to damaged DNA but did not 
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impair RPA accumulation	(Figure 2b,e,f;S2e,f). These data suggest that ETAA1 
contains two RPA-binding determinants that jointly underlie its stable retention at 
DNA damage sites.	
 
ETAA1 contains an ATR-activating domain 
We next asked how ETAA1 functions in the DDR. Strikingly, overexpression of full-
length ETAA1 led to strong, pan-nuclear γH2AX positivity independently of its 
binding to RPA (Figure 3a,b). Instead, deleting N-terminal portions of ETAA1 
suppressed its ability to promote γH2AX formation, and overexpression of these 
regions alone was sufficient to trigger H2AX phosphorylation, similar to the TopBP1 
ATR-activating domain (AAD) (Figure 3a,b;S3a,b)39. Using ETAA1 deletion 
constructs, we mapped the minimal γH2AX-promoting determinant in ETAA1 to 
amino acids 56-220, a conserved region harboring a predicted coiled coil domain 
(Figure 3a-c;S3a,b). For reasons described below, we refer to this region as AAD 
(ATR-activating domain) (Figure 3c;S3a). In-frame deletion of this sequence (ΔAAD) 
had no impact on ETAA1 recruitment to DNA damage sites but abolished γH2AX 
formation upon ETAA1 overexpression (Figure 3a,b), further suggesting that this 
activity is uncoupled from its RPA-binding ability. To characterize the ability of 
ETAA1-AAD to induce γH2AX formation, we fused this sequence to GFP and an 
estrogen receptor variant (ERT2), allowing for swift nuclear translocation of 
otherwise cytoplasmic GFP-ETAA1-AAD-ERT2 upon treatment with 4-hydroxy-
tamoxifen (4-OHT) (Figure 3c,d). Exposure of cells stably expressing GFP-ETAA1-
AAD-ERT2 to 4-OHT triggered rapid and robust pan-nuclear γH2AX positivity 
irrespective of cell cycle position (Figure 3d-f;S3c). This effect resembled that of an 
analogous system for 4-OHT-controlled nuclear expression of TopBP1-AAD39, 
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however ETAA1-AAD promoted γH2AX formation at lower expression levels than 
TopBP1-AAD (Figure S3d). Several lines of evidence suggested that similar to 
TopBP1-AAD39, the γH2AX positivity caused by ETAA1-AAD overexpression was 
not a consequence of DNA breakage: First, the ETAA1-AAD-induced γH2AX signal 
was pan-nuclear rather than focal (Figure 3a,d,e) and it was not accompanied by RPA 
foci formation and chromatin loading (Figure S3e). Second, treatment with kinase 
inhibitors or siRNAs showed that the γH2AX-promoting ability of ETAA1-AAD was 
independent of the DSB-responsive kinases ATM and DNA-PK, whereas the kinase 
activity of ATR was essential (Figure 3f; see also Figure S6a-c).  
 
Because ATR is capable of phosphorylating H2AX like ATM and DNA-PK40, these 
data suggested that ETAA1-AAD directly stimulates ATR kinase activity similar to 
TopBP1-AAD. Indeed, both full-length ETAA1 and ETAA1-AAD alone interacted 
with ATR in co-immunoprecipitation assays (Figure 3g;S3f). When incubated with 
purified ATR-ATRIP complex, recombinant ETAA1-AAD markedly stimulated ATR 
kinase activity towards MCM2 in vitro (Figure 3h), strongly suggesting that this 
domain is a bona fide AAD. The TopBP1-AAD contains a conserved tryptophan 
residue (W1145 in human TopBP1) that is essential for its ability to stimulate ATR 
kinase activity26. Strikingly, the sequence spanning this residue displayed similarity to 
a region within ETAA1-AAD, and targeted point mutations of aromatic amino acids 
in this sequence (AADmut) were sufficient to abrogate γH2AX formation triggered by 
overexpression of full-length ETAA1 or its AAD alone (Figure 3a-c;S3a). 
Interestingly, ETAA1-AAD contains several potential ATR phosphorylation sites and 
was phosphorylated by ATR in vitro (Figure 3h;S3a). Moreover, endogenous ETAA1 
showed a prominent ATR-dependent mobility shift after replication stress (Figure 
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S3g), suggesting that it undergoes phosphorylation by ATR in response to such 
insults. Finally, mass spectrometry-based analysis of ATR-dependent phosphorylation 
changes induced by ETAA1-AAD overexpression showed that many ATR 
phosphorylation sites, including two in ETAA1-AAD itself, were significantly 
upregulated under these conditions (Figure 3i;S3h,i;Table S4). We confirmed 
biochemically for H2AX and Chk1 that nuclear overexpression of ETAA1-AAD 
enhanced their ATR-dependent phosphorylation (Figure 3j). Altogether, these results 
demonstrate that ETAA1 harbors an AAD capable of directly and potently stimulating 
ATR kinase activity.  
 
ETAA1 promotes ATR-mediated signaling and cell survival after replication stress 
Prompted by the findings above, we generated human HCT116 cell lines with 
targeted ETAA1 knockout (ETAA1Δ) to investigate whether ETAA1 promotes ATR 
signaling upon genotoxic stress. Indeed, while ablation of ETAA1 expression did not 
markedly affect overall cell cycle distribution (Figure S4a), ATR-dependent 
phosphorylation of RPA2 at S33 in response to CPT treatment was strongly 
diminished in HCT116 ETAA1Δ cells (Figure 4a-c). Likewise, RPA2 S4/S8 
phosphorylation, which occurs downstream of S33 phosphorylation in CPT-treated 
cells41, was clearly defective in ETAA1Δ cells (Figure 4a,b). Similar effects could be 
seen in HeLa cells ablated for ETAA1 expression (Figure S4b,c). Importantly, 
ETAA1 knockout did not impair RPA loading at CPT-induced DSBs (Figure 4b-e), 
suggesting that ETAA1 loss impairs the response to CPT at the level of checkpoint 
signaling but not ssDNA generation via DSB end resection. In response to HU-
induced helicase-polymerase uncoupling, ATR is essential to prevent RPA exhaustion 
and fork breakage by suppressing new origin firing, and inhibition of ATR in HU-
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treated cells therefore leads to excessive DSB formation and RPA 
hyperphoshorylation42. Consistently, HU-treated ETAA1Δ cells showed increased 
levels of RPA2 phosphorylation similar to the effect of ATR inhibition (Figure 
S4d)42. In contrast, ATR-dependent phosphorylation of Chk1 after treatment with 
CPT or HU was not markedly altered in ETAA1-deficient cells (Figure 4a;S4c), 
indicating that loss of ETAA1 differentially affects ATR substrates. 
 
Further supporting a role of ETAA1 in promoting ATR signaling, loss of ETAA1 
rendered cells highly sensitive to replication stress induced by HU, CPT or 
Mitomycin C (MMC), but not to clastogens such as Etoposide that generate DSBs 
independently of replication (Figure 4f-h;S4e-g). Depletion of ETAA1 by siRNAs 
phenocopied the effect of ETAA1 knockout in cell survival assays (Figure S4h-j). 
Importantly, complementation of ETAA1Δ cells with ectopic ETAA1 wild-type (WT), 
but not the ΔRBM1+2, ΔAAD and AADmut mutants, fully rescued their 
hypersensitivity to CPT and partially restored survival after HU or MMC (Figure 4f-
h;S4k,l). Because ETAA1 is a potent ATR activator, it is possible that expression of 
stably reconstituted GFP-ETAA1 at levels above that of endogenous ETAA1 (Figure 
S4k) may adversely affect cellular responses to certain genotoxic agents. We 
conclude that ETAA1 has an important role in promoting cell survival following 
replication stress, in a manner that requires both its ATR-activating and RPA-binding 
abilities. 
 
ETAA1 is required for DNA replication integrity 
We performed DNA fiber assays to understand how the absence of ETAA1 sensitizes 
cells to replication stress. By labeling cells with consecutive pulses of 
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chlorodeoxyuridine (CldU) and 5’-iododeoxyuridine (IdU), we found that ETAA1 
deficiency in both HCT116 and HeLa cells caused a strong reduction in replication 
fork speed in otherwise unperturbed cells (Figure 5a;S5a). Moreover, ETAA1-
deficient cells showed marked asymmetry of bidirectional replication forks from 
individual replication origins (Figure 5b;S5b), suggesting that ETAA1 loss gives rise 
to a higher incidence of fork pausing and stalling. The diminished fork speed in 
ETAA1Δ cells was unexpected, given the similar cell cycle and EdU incorporation 
profiles of WT and ETAA1Δ cells (Figure S4a,b). However, we found that in both 
HCT116 and HeLa ETAA1Δ cells, the slower fork progression in ETAA1Δ cells was 
accompanied by a dramatically increased rate of new origin firing (Figure 5c;S5c). 
Hence, loss of ETAA1 deregulates DNA replication initiation and elongation, similar 
to reported effects of ATR inhibition43. These defects were fully corrected by stably 
reconstituted WT ETAA1 (Figure 5a-c). Further supporting a key role of ETAA1 in 
promoting ATR signaling during replication, we found that the basal γH2AX level in 
unstressed cells, which was ATR-dependent and restricted to S/G2 phase cells, was 
also prominently reduced in ETAA1Δ cells, whereas depletion of TopBP1 had no 
effect (Figure 5d;S5d-g).  
 
We next assessed how ETAA1 loss affects DNA replication status after fork-stalling 
insults. When cells were pulse-labeled with CldU and then with IdU in the presence 
of CPT, ETAA1 was again important for suppressing fork progression defects and 
new origin firing, in an AAD-dependent manner (Figure 5e,f). In separate 
experiments, we found that ETAA1Δ cells subjected to prolonged low-dose treatment 
with the DNA polymerase inhibitor Aphidicolin showed markedly elevated levels of 
abnormal nuclei and micronuclei as well as 53BP1 nuclear bodies in G1 phase44 
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(Figure 5g,h), further demonstrating a compromised ability of these cells to respond 
to replication problems. These data show that like ATR, ETAA1 is important for the 
integrity of DNA replication during both unperturbed and stressful conditions.  
 
ETAA1 and TopBP1 function in independent but parallel ATR activation pathways 
Because both ETAA1 and TopBP1 contain AADs, we reasoned that they might 
cooperatively promote ATR-dependent signaling after replication stress. We therefore 
asked whether they function in joint or separate ATR activation pathways. 
Knockdown of TopBP1 or the 9-1-1 subunit Rad9 had no effect on the ability of 
ETAA1-AAD to stimulate ATR kinase activity (Figure S6a-c). Likewise, ETAA1 did 
not impair the ability of TopBP1-AAD to enhance ATR activity (Figure S6d), 
suggesting that ETAA1 and TopBP1 function in independent ATR activation 
pathways. Remarkably, however, whereas individual depletion of TopBP1 or ETAA1 
from HCT116 cells only had a modest impact on cellular fitness, simultaneous loss of 
these proteins profoundly impaired cell proliferation (Figure 6a) and led to strongly 
increased rates of spontaneous DNA breakage in otherwise undamaged cells, as 
evidenced by neutral comet assays and markers of ATM kinase activity, including 
H2AX, RPA2 S4/S8 and Chk2 T68 phosphorylation (Figure 6b-e). This phenotype 
mimicked the effect of persistent ATR inhibition and could be seen in both HCT116 
and HeLa ETAA1Δ cells, as well as after siRNA-mediated co-depletion of ETAA1 
and TopBP1 (Figure 6b-e;S6e-g). Quantitative image analysis revealed that depletion 
of TopBP1 from ETAA1Δ cells led to strongly elevated levels of chromatin-bound 
RPA accompanied by γH2AX formation (Figure 6c), suggesting that simultaneous 
loss of ETAA1 and TopBP1 leads to massive replication fork collapse42. A substantial 
proportion of these cells displayed fragmented nuclei with sub-G1 DNA content 
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(Figure 6c,d;S6h), a phenotype also observed after loss of ATR kinase activity15, 45. 
Cells lacking both ETAA1 and TopBP1 progressed abnormally through mitosis and 
frequently stained positive for γH2AX and the mitotic marker H3 pS10 (Figure 
S6i;Video S1,S2), suggesting that they have a defective G2/M checkpoint and enter 
mitosis prematurely in the presence of DNA damage. In contrast, apoptosis inhibitors 
did not suppress nuclear fragmentation following combined ETAA1 and TopBP1 loss 
(Figure S6j), suggesting this phenotype mostly results from mitotic catastrophe. 
Complementation of ETAA1Δ cells with ectopic WT ETAA1, but not AAD- and RPA 
binding-deficient mutants, reversed Chk2 and RPA2 hyper-phosphorylation resulting 
from TopBP1 knockdown in this background (Figure 6g). These data suggested that 
ETAA1 and TopBP1 operate in parallel pathways of ATR regulation, and that their 
simultaneous inactivation is detrimental to genome integrity and cell survival by 
causing robust impairment of ATR signaling. Consistently, whereas depletion of 
ETAA1 or TopBP1 alone did not markedly impact ATR-dependent Chk1 
phosphorylation in HCT116 and HeLa cells, simultaneous loss of these proteins 
strongly reduced Chk1 phosphorylation levels (Figure 6b,g;S6e). Stable expression of 
ETAA1 WT but not AAD- and RPA binding-deficient mutants restored Chk1 
phosphorylation in ETAA1Δ cells depleted of TopBP1 (Figure 6g). Finally, ETAA1Δ 
cells were more sensitive to low concentrations of ATR inhibitors than WT cells 
(Figure 6h), suggesting that loss of ETAA1 decreases the overall cellular capacity to 
activate ATR. Collectively, these findings suggest that ETAA1 functions in parallel 
with, but independent of, the canonical TopBP1 pathway in stimulating ATR kinase 
activity, and that both pathways make important contributions to ATR-mediated 
responses to replication stress. 
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ETAA1 and TopBP1 jointly promote ATR signaling in cancer cell lines 
To further test the emerging model of ATR activation involving parallel TopBP1- and 
ETAA1-dependent pathways, we analyzed ETAA1 expression status in a panel of 
human cancer cell lines. While the abundance of ETAA1 showed considerable 
variation across cell lines, we noted that U2OS osteosarcoma cells express 
abnormally low levels of ETAA1, which did not reflect reduced abundance of ETAA1 
mRNA compared to other cell lines (Figure 7a;S7a,b). Using the protein synthesis 
inhibitor Cycloheximide (CHX), we found that unlike in HeLa cells, the halflife of 
ETAA1 was very short in U2OS cells (Figure S7c), possibly accounting for their low 
ETAA1 expression levels. This provided a framework to further test the biological 
relevance of ETAA1 for ATR activation. Strikingly, we found that knockdown of 
TopBP1 quantitatively suppressed HU-induced Chk1 phosphorylation in U2OS cells 
but not in HeLa cells that express higher levels of ETAA1 (Figure 7b). In contrast, 
depleting TopBP1 from U2OS cells stably expressing GFP-ETAA1 had little effect 
on Chk1 phosphorylation after HU treatment (Figure 7b). Similarly, loss of TopBP1 
in U2OS but not HeLa cells markedly impaired ATR-dependent H2AX 
phosphorylation after HU-induced fork stalling, almost mimicking complete ATR 
inhibition, and this defect could be at least partially reversed by stable expression of 
GFP-ETAA1 in U2OS cells (Figure 7b-d). Consistently, combined knockdown of 
TopBP1 and ETAA1 was necessary to suppress ATR-dependent H2AX 
phosphorylation after HU treatment in HeLa cells, while depletion of either factor 
alone had little effect (Figure S7d-f). These findings provide further evidence that 
ETAA1 and TopBP1 function in independent but converging branches of ATR 
activation after replication stress (Figure 7e).  
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Discussion 
Detailed insights into the molecular framework governing ATR signaling are central 
to understanding how cells counteract genetic alterations and severe pathologies that 
may arise as a consequence. Stimulation of ATR kinase activity depends on AAD-
containing proteins, three of which contribute to promoting Mec1/ATR-dependent 
signaling during S phase in budding yeast30. Activation of vertebrate ATR is thought 
to rely largely on a pathway mediated by TopBP1, the only factor in higher 
eukaryotes known to harbor an AAD. Here, we have shown that ATR activation is not 
exclusively mediated by this pathway, but that human cells possess a second ATR-
stimulatory mechanism that centers on ETAA1 (Figure 7e), a previously 
uncharacterized protein that undergoes enrichment at DNA damage sites via dual 
RPA1- and RPA2-binding motifs and contains a bona fide AAD. Similar findings 
were reported by Cortez and colleagues (Nature Cell Biology, this issue). The ETAA1 
AAD is a potent inducer of ATR kinase activation and is essential for the ability of 
ETAA1 to promote ATR signaling, replication integrity, and cell survival. While the 
known AADs share little sequence homology, Mec1/ATR activation by these 
domains involves pairs of aromatic amino acids whose spacing varies substantially 
among individual AADs30, 46. Interestingly, the sequence spanning a conserved 
aromatic residue within the TopBP1 AAD that is essential for its ability to promote 
ATR activation26 shows homology to a region within ETAA1-AAD, point mutations 
of which prevent ATR activation by full-length ETAA1. Thus, the TopBP1 and 
ETAA1 AADs likely stimulate ATR kinase activity by analogous mechanisms.  
 
The combination of RPA-binding and AAD motifs within ETAA1 may render it a 
potent ATR activator by obviating the need for ancillary factors targeting it to ATR-
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ATRIP complexes at genotoxic stress sites. Indeed, ETAA1 promotes ATR activation 
independently of the canonical TopBP1/9-1-1 axis, however it remains to be seen 
whether ETAA1 collaborates with other factors in this process. Studies in mice have 
shown that the integrity of the TopBP1 AAD is essential for viability28. Our data 
suggest that the ETAA1 and TopBP1 pathways jointly promote ATR signaling, and 
that both pathways must be inactivated to robustly suppress ATR kinase activity in 
cells, illustrated by the synthetic lethality caused by combined ETAA1 and TopBP1 
loss. An important question arising from these findings concerns the distribution of 
labor between TopBP1 and ETAA1 in activating ATR after different genotoxic 
stimuli. Conceivably, they could act on distinct pools of RPA-ssDNA-bound ATR-
ATRIP complexes at DNA damage sites. ETAA1 might be particularly important for 
stimulating ATR kinase activity when long stretches of RPA-coated ssDNA are 
produced, such as during DSB end resection, where most ATR-ATRIP would be out 
of reach of 9-1-1-bound TopBP1 at ssDNA-dsDNA junctions. A similar role in 
promoting ATR kinase activity away from ssDNA-dsDNA junctions was recently 
suggested for the MRN component Nbs1, albeit in a manner that required TopBP141. 
Recent work has shown that two distinct modes of Mec1/ATR signaling exist in 
yeast, one of which is highly active during normal replication but uncoupled from the 
canonical replication stress-induced checkpoint signaling pathway involving Mec1/ 
Rad5347. It is tempting to speculate that the existence of two AAD-containing proteins 
in vertebrates may similarly enable different modes of ATR signaling in accordance 
with the status and integrity of DNA replication.  
 
In preclinical studies, ATR kinase inhibitors have shown promising potential in 
cancer therapy, exacerbating oncogene-induced replication stress to sensitize cancer 
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cells but not normal cells to DNA damage48. The functional status of ETAA1 in 
cancer cells, which typically experience high loads of replication stress49, may be an 
important determinant of their relative sensitivity to ATR inhibitors, since loss of 
ETAA1 leads to markedly reduced survival rates after treatment with these agents, 
particularly at low doses. This may be of clinical relevance, as the levels of ETAA1 
expression vary considerably among different cancer cell lines and has important 
bearings on how ATR-dependent signaling responses are instigated in different 
genetic backgrounds. Of note, variations in the ETAA1 locus are associated with 
increased pancreatic cancer risk50, 51. By promoting ATR-dependent responses to 
replication stress, ETAA1 may be an important factor in the cellular defence against 
cancer and other diseases associated with genomic instability. 
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Figure legends 
 
Figure 1. 
Systematic profiling of DSB-containing chromatin reveals ETAA1 as a potential 
DDR factor 
a. CHROMASS workflow to analyze protein recruitment to DSB-containing 
chromatin. Sperm chromatin was incubated in Xenopus egg extract and DSBs induced 
by addition of PflMI enzyme. After various times, chromatin was isolated by 
centrifugation through a sucrose cushion and analyzed by label-free mass 
spectrometry. b. Heatmap showing the mean of the z-scored LFQ protein intensities 
of selected factors for DSB-containing chromatin normalized to the undamaged 
control (n=3). See Table S2 for recruitment profiles for all quantified proteins. c. 
Protein recruitment to DSB-containing chromatin at 15 min compared to an 
undamaged control. The volcano plot shows the mean difference of the protein 
intensity (log2) plotted against the p-value resulting from a one-sided modified t-test 
(see Methods, n=3 for both groups). Dashed line indicates the significance cut-off. d. 
Protein recruitment to DSB-containing chromatin at 45 min, plotted as in (c). e. U2OS 
cells stably expressing GFP-ETAA1 were subjected to laser microirradiation, fixed 1 
h later and co-immunostained with RPA1 and γH2AX antibodies. f. Quantification of 
data in (e) (mean±SD;n=3; 80 cells analyzed per experiment). g. U2OS cells stably 
expressing GFP-ETAA1 were treated with CPT (1 h) or HU (3 h), fixed and co-
immunostained with RPA1 and γH2AX antibodies. All scale bars, 10 µm. Data are 
representative of three (e) and two (g) independent experiments with similar results.  
 
Figure 2. 
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ETAA1 is recruited to DNA damage sites through interaction with RPA 
a. Representative images of U2OS cells stably expressing GFP-ETAA1 that were 
transfected with indicated siRNAs and subjected to laser microirradiation, followed 
by co-immunostaining with RPA1 and γH2AX antibodies. Knockdown efficiency of 
siRNAs is shown in Figure S2a. b. U2OS cells transfected with constructs encoding 
indicated versions of GFP-ETAA1 or empty vector (EV) were subjected to GFP 
immunoprecipitation (IP) followed by immunoblotting for the indicated proteins. c. 
As in (b), except that cells were transfected with indicated GFP-RPA2 constructs or 
empty vector (EV). SMARCAL1 is a positive control for RPA2 binding. d. Schematic 
diagram of human ETAA1 protein, indicating the locations of conserved RPA1- and 
RPA2-binding motifs (RBM1 and RBM2). Alignments of these sequences with 
RPA1/2-binding motifs from other proteins are shown. Conserved key residues within 
the RPA-binding motifs are highlighted. e. Representative images of U2OS cells 
stably expressing wild-type (WT) and mutant forms of GFP-ETAA1 subjected to 
laser microirradiation followed by immunostaining with γH2AX antibody. f. 
Quantification of data in (e) (mean±SD;n=3; approx. 200 cells counted per condition). 
All scale bars, 10 µm. Data are representative of three (a,b,e) and two (c) independent 
experiments with similar results. Uncropped blots (b,c) are shown in Figure S8. 
 
Figure 3. 
ETAA1 contains an ATR-activating domain (AAD) 
a. U2OS cells transfected with indicated GFP-ETAA1 constructs or empty vector 
(EV) expressing GFP only were immunostained with γH2AX antibody. b. 
Quantification of data in (a) (mean±SD;n=3; 240 cells counted per condition). c. 
Schematic diagram of human ETAA1 protein, indicating location of the ATR-
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activating domain (AAD), its sequence similarity to the TopBP1 AAD, and the 
construct used for inducible nuclear translocation of ETAA1-AAD upon 4-OHT 
treatment. d. U2OS cells expressing GFP-ETAA1-AAD-ERT2 were treated or not 
with 4-OHT for 2 h and immunostained with γH2AX antibody. e. Cells in (d) were 
analyzed by quantitative imaging (bottom). Representative images are shown (top). f. 
As in (e), except that cells were treated with indicated kinase inhibitors 10 min before 
addition of 4-OHT for 1 h (mean±SD;n=3; >3000 cells analyzed per condition). g. 
U2OS cells transfected with empty vector (EV) or GFP-ETAA1 expression construct 
were subjected to GFP immunoprecipitation (IP) followed by immunoblotting for the 
indicated proteins. h. In vitro kinase assay, using purified ATR-ATRIP complex, 
recombinant ETAA1-AAD and MCM2(79-138) fragments (the latter serving as ATR 
model substrate) and radioactive ATP (32P). Reactions were resolved on SDS-PAGE, 
stained with Colloidal Blue (CB), and 32P incorporation was assessed by 
autoradiography. i. Phospho-proteomic analysis of SILAC-labeled U2OS/GFP-
ETAA1-AAD-ERT2 cells treated or not with 4-OHT for 2 h to monitor 
phosphorylation changes triggered by forced nuclear expression of ETAA1-AAD. To 
identify ATR-dependent changes, ATR inhibitor (ATRi) or vehicle was added 15 min 
before 4-OHT treatment in an independent SILAC experiment (see Figure S3h for 
experimental set-up). Scatterplot shows the log2 of mean SILAC ratios from four 
independent replicates of each experiment plotted against each other (see Table S4 for 
full data). j. Immunoblot analysis of U2OS/GFP-ETAA1-AAD-ERT2 cells treated 
with 4-OHT for indicated times in the absence or presence of ATR inhibitor (ATRi). 
All scale bars, 10 µm. Data are representative of three (a,d,e,h) and two (g,j) 
independent experiments with similar results. Uncropped blots (g-j) are shown in 
Figure S8. 
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Figure 4. 
ETAA1 promotes cell survival and ATR signaling after replication stress 
a. Immunoblot analysis of parental HCT116 (WT) cells and derivative ETAA1 
knockout lines (ETAA1Δ) exposed to CPT for various times. Asterisk demarcates an 
unspecific band detected by the ETAA1 antibody. b. Chromatin-enriched and soluble 
fractions of HCT116 WT and ETAA1Δ cell lines left untreated or exposed to CPT for 
90 min were immunoblotted with indicated antibodies. c. HCT116 WT and ETAA1Δ 
cell lines left untreated or exposed to CPT were co-immunostained with RPA2 and 
RPA2-pS4/S8 antibodies. d. As in (c), except that cells were co-immunostained with 
γH2AX and RPA1 antibodies. e. Quantification of data in (d). γH2AX-negative and -
positive cell populations were gated and analyzed for mean RPA1 chromatin loading 
per nucleus by quantitative imaging. Box plot shows median, upper and lower 
quartiles, 95% values (whiskers) and outliers (n=2000 cells per condition). f. 
Clonogenic survival of HCT116 WT, HCT116 ETAA1Δ, and HCT116 ETAA1Δ cells 
stably reconstituted with GFP-ETAA1 that were subjected to various doses of HU for 
24 h (mean±SEM;n=3). g. As in (f), except that cells were subjected to indicated 
doses of MMC (mean±SEM;n=3). h. As in (f), except that cells were treated with 
indicated doses of CPT (mean±SEM;n=3). All scale bars, 10 µm. Data are 
representative of three (a,b) and two (c-e) independent experiments with similar 
results. Uncropped blots (a,b) are shown in Figure S8. 
 
Figure 5. 
ETAA1 promotes DNA replication integrity during unperturbed and stressful 
conditions 
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a. DNA fiber analysis of HCT116 WT and ETAA1Δ cells labeled with CldU (20 min; 
red) followed by IdU (20 min; green). Fork speeds were calculated as length of 
labeled track divided by pulse time. Red bars denote median fork speed (400 fibers, 
pooled from two independent experiments, analyzed per condition). Representative 
fibers are shown. b. Fork symmetry was calculated as the percentage of shorter 
divided by longer tracks from (a). Concordance is 100%, representing fully 
bidirectional replication and equal rates of elongation for both daughter forks. Red 
bars denote median fork symmetry rate (50 bidirectional forks, pooled from two 
independent experiments, analyzed per condition). Representative fibers displaying 
fork symmetrical and asymmetrical bidirectional replication forks are shown. c. As in 
(a), except that the proportion of new origins (IdU-only tracks) was determined (200 
fibers analyzed per condition per experiment). d. Quantitative image analysis of 
HCT116 cells treated with indicated siRNAs and immunostained with γH2AX 
antibody. The proportion of γH2AX-positive cells (pink, arbitrary cut-off) is indicated 
(n=2000 cells per condition). e. DNA fiber analysis of HCT116 WT and ETAA1Δ 
cells labeled with CldU (20 min) followed by IdU and CPT (40 min). New origin 
firing was determined as in (c) (200 fibers analyzed per condition per experiment). f. 
Fork progression (CldU- and IdU-positive tracks) in cells from (e). g. HCT116 WT 
and ETAA1Δ cells left untreated or grown in the presence of Aphidicolin (0.2 µM) for 
24 h were stained with DAPI, and nuclear aberrations (right, representative examples) 
were assessed (mean±SD;n=3; at least 200 cells were counted per condition). h. As in 
(g), except that cells were co-immunostained with 53BP1 and Cyclin A antibodies. 
53BP1 bodies in Cyclin A-negative (G1 phase) cells (representative examples shown, 
right) were enumerated (red lines, median; 150 cells analyzed per condition). Data are 
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representative of three (d,g,h) independent experiments with similar results. Source 
data (a-c,e,f,h) are provided in Table S5. 
 
Figure 6. 
ETAA1 and TopBP1 promote parallel, but independent, pathways of ATR 
activation 
a. Colony formation assay, using HCT116 WT and ETAA1Δ cell lines transfected 
with non-targeting control (CTRL) or TopBP1 siRNAs (mean±SD;n=3). b. 
Immunoblot analysis of HCT116 WT and ETAA1Δ cells transfected with TopBP1 
siRNAs for the indicated times. Asterisk demarcates an unspecific band detected by 
the ETAA1 antibody. c. HCT116 WT and ETAA1Δ cell lines transfected with non-
targeting control (CTRL) or TopBP1 siRNAs were analyzed by quantitive imaging. 
The color of each dot (cell nucleus) represents the mean γH2AX intensity (low: grey; 
high: red); >2000 cells analyzed per condition. d. Representative images from the 
experiment shown in (c). Scale bar, 10 µm. e. DSB formation in cells in (b) was 
monitored by the neutral Comet assay. Tail lengths of at least 70 nuclei were 
measured for each condition. f. DNA content of cells in (d) was analyzed by 
quantitative imaging. The proportion of cells with sub-G1 DNA content (pink) is 
indicated. g. HCT116 WT, HCT116 ETAA1Δ-1 and HCT116 ETAA1Δ-1 cells stably 
reconstituted with indicated GFP-ETAA1 expression constructs were transfected with 
non-targeting control (−) or TopBP1 siRNA and immunoblotted with indicated 
antibodies. h. Viability of HCT116 WT and ETAA1Δ cell lines grown in the presence 
of various doses of ATR inhibitor (ATRi) was assayed by measuring cell growth with 
the SRB assay (mean±SD;n=3). *p<0.05, multiple t-test corrected with Holm-Sidak 
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method. Data are representative of three (b,d,f,g) and two (c,e) independent 
experiments with similar results. Source data (e) are provided in Table S5. 
Uncropped blots (b,g) are shown in Figure S8. 
 
Figure 7. 
ETAA1 and TopBP1 both contribute to ATR signaling in cancer cell lines 
a. Immunoblot analysis of ETAA1 and other proteins involved in ATR activation in 
indicated exponentially growing human cancer cell lines and Tig3 diploid embryonic 
lung fibroblasts. b. HeLa, U2OS and U2OS/GFP-ETAA1 cells were transfected with 
TopBP1 siRNAs, treated with HU for 3 h and processed for immunoblotting with 
indicated antibodies. c. HeLa and U2OS cells transfected with indicated siRNAs were 
treated with HU and ATR inhibitor (ATRi) for 3 h as indicated. Cells were then co-
immunostained with γH2AX and RPA1 antibodies and analyzed by quantitative 
imaging (n=1500 cells per condition). The contribution of ATR to the γH2AX signal, 
based on the ATRi-treated sample, is indicated in blue. Cells displaying maximal HU-
induced RPA chromatin loading accompanied by ATM-dependent but ATR-
independent H2AX hyperphosphorylation reflecting fork breakage42 are indicated in 
pink. d. As in (c), but using U2OS and U2OS/GFP-ETAA1 cells (n=1500 cells per 
condition). e. Model of parallel ETAA1- and TopBP1-mediated stimulation of ATR 
kinase activity at RPA-coated ssDNA regions (see main text for details). Change of 
color represents ATR activation. Data are representative of three (b) and two (a,c,d) 
independent experiments with similar results. Uncropped blots (a,b) are shown in 
Figure S8. 
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